Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Politicians: 'Bring Pharma Manufacturing Back To Europe'

EFPIA Expresses Concern About Some Proposals In Report

Executive Summary

The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation. 

You may also be interested in...

Reality Check On UK Production Capacity For COVID-19 Treatments

In the first of a two-part series of articles on the UK COVID-19 Therapeutics Task Force, the Pink Sheet reports on how task force members are examining the role of therapeutics in tackling the pandemic and why the UK’s manufacturing capability needs to be strengthened so it can meet future demand. The second article will cover the work of the task force and how it is structured to identify and advance promising coronavirus treatments

Manufacturing Incentives, Flexible Regulations Seen As Remedy For EU Drug Shortages

A committee of influential politicians in Europe are calling for measures that will see the EU become more self-sufficient in the production of medicines, thereby reducing medicine shortages and dependence on imports from third countries.

Bigger Trials, More RWE Needed for Future Crisis Response, Say EU Regulators

A report from the EU medicines regulatory network looks at what was done well in the response to the COVID-19 pandemic, and what needs to be improved if we are to be better prepared next time. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts